Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bd6ce6bf4ab9078ffda77ad5f62a02747> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bd6ce6bf4ab9078ffda77ad5f62a02747 NCIT_P378 "NCI" @default.
- Bd6ce6bf4ab9078ffda77ad5f62a02747 type Axiom @default.
- Bd6ce6bf4ab9078ffda77ad5f62a02747 annotatedProperty IAO_0000115 @default.
- Bd6ce6bf4ab9078ffda77ad5f62a02747 annotatedSource NCIT_C102754 @default.
- Bd6ce6bf4ab9078ffda77ad5f62a02747 annotatedTarget "An orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic activity. Upon oral administration, ensartinib binds to and inhibits ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors; ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors." @default.